New treatment in adults with untreated chronic lymphocytic leukemia

What we are studying

The purpose of this study is to compare the effects, good and/or bad, of two different therapies that include combinations of the drugs rituximab, fludarabine, cyclophosphamide and the study drug have on study participants and their CLL. The first three of these drugs are standard treatments for CLL.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • Native Hawaiian or Pacific Islander
  • All Ethnicities
  • Ages 18 - 70

Eligibility Criteria

  • Diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL) that has progressed to the point it requires treatment

What is involved

  • Arm A includes 7 28-day cycles and doctor visits every 3 months thereafter
  • Arm B includes up to 6 cycles (cycle = 28 days) as long as the disease does not get worse and the study participant is tolerating the medication



Contact Information

Study Coordinator
Kimberly Sweat

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.